Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2017 Jul 12;8:808. doi: 10.3389/fimmu.2017.00808

Family History of Early Infant Death Correlates with Earlier Age at Diagnosis But Not Shorter Time to Diagnosis for Severe Combined Immunodeficiency

Anderson Dik Wai Luk 1, Pamela P Lee 1, Huawei Mao 1,2, Koon-Wing Chan 1, Xiang Yuan Chen 3, Tong-Xin Chen 4, Jian Xin He 5, Nadia Kechout 6, Deepti Suri 7, Yin Bo Tao 3, Yong Bin Xu 8, Li Ping Jiang 9, Woei Kang Liew 10, Orathai Jirapongsananuruk 11, Tassalapa Daengsuwan 12, Anju Gupta 7, Surjit Singh 7, Amit Rawat 7, Amir Hamzah Abdul Latiff 13, Anselm Chi Wai Lee 14, Lynette P Shek 15, Thi Van Anh Nguyen 16, Tek Jee Chin 17, Yin Hsiu Chien 18, Zarina Abdul Latiff 19, Thi Minh Huong Le 16, Nguyen Ngoc Quynh Le 16, Bee Wah Lee 15, Qiang Li 20, Dinesh Raj 21, Mohamed-Ridha Barbouche 22, Meow-Keong Thong 23, Maria Carmen D Ang 24, Xiao Chuan Wang 25, Chen Guang Xu 26, Hai Guo Yu 27, Hsin-Hui Yu 18, Tsz Leung Lee 1, Felix Yat Sun Yau 28, Wilfred Hing-Sang Wong 1, Wenwei Tu 1,2, Wangling Yang 1,2, Patrick Chun Yin Chong 1, Marco Hok Kung Ho 1, Yu Lung Lau 1,2,*
PMCID: PMC5506088  PMID: 28747913

Abstract

Background

Severe combined immunodeficiency (SCID) is fatal unless treated with hematopoietic stem cell transplant. Delay in diagnosis is common without newborn screening. Family history of infant death due to infection or known SCID (FH) has been associated with earlier diagnosis.

Objective

The aim of this study was to identify the clinical features that affect age at diagnosis (AD) and time to the diagnosis of SCID.

Methods

From 2005 to 2016, 147 SCID patients were referred to the Asian Primary Immunodeficiency Network. Patients with genetic diagnosis, age at presentation (AP), and AD were selected for study.

Results

A total of 88 different SCID gene mutations were identified in 94 patients, including 49 IL2RG mutations, 12 RAG1 mutations, 8 RAG2 mutations, 7 JAK3 mutations, 4 DCLRE1C mutations, 4 IL7R mutations, 2 RFXANK mutations, and 2 ADA mutations. A total of 29 mutations were previously unreported. Eighty-three of the 94 patients fulfilled the selection criteria. Their median AD was 4 months, and the time to diagnosis was 2 months. The commonest SCID was X-linked (n = 57). A total of 29 patients had a positive FH. Candidiasis (n = 27) and bacillus Calmette–Guérin (BCG) vaccine infection (n = 19) were the commonest infections. The median age for candidiasis and BCG infection documented were 3 months and 4 months, respectively. The median absolute lymphocyte count (ALC) was 1.05 × 109/L with over 88% patients below 3 × 109/L. Positive FH was associated with earlier AP by 1 month (p = 0.002) and diagnosis by 2 months (p = 0.008), but not shorter time to diagnosis (p = 0.494). Candidiasis was associated with later AD by 2 months (p = 0.008) and longer time to diagnosis by 0.55 months (p = 0.003). BCG infections were not associated with age or time to diagnosis.

Conclusion

FH was useful to aid earlier diagnosis but was overlooked by clinicians and not by parents. Similarly, typical clinical features of SCID were not recognized by clinicians to shorten the time to diagnosis. We suggest that lymphocyte subset should be performed for any infant with one or more of the following four clinical features: FH, candidiasis, BCG infections, and ALC below 3 × 109/L.

Keywords: severe combined immunodeficiency, family history, candidiasis, absolute lymphocyte count, newborn screening

Introduction

Severe combined immunodeficiency (SCID) is a group of genetic diseases causing profound developmental and functional impairment of T cells, affecting cellular and humoral immunities. Currently, at least 49 genes are identified to be responsible for SCID and its variants (13). Of all the SCID genes, the commonest gene involved is the IL-2 receptor gamma chain gene (IL2RG), which accounted for 45 and 19% of SCID cases before and after the T-cell receptor excision circle (TREC) newborn screening, and was introduced in USA (35). Patients typically present with recurrent infections from opportunistic pathogens and live-attenuated vaccines, such as bacillus Calmette–Guérin (BCG) (6), chronic diarrhea, and failure to thrive (FTT), eventually die within the first 2 years of life if left untreated (7). Patients typically have low absolute lymphocyte count (ALC). They have been classified by the number of B lymphocytes as B+ or B− and recently by the causative genetic mutation.

The definitive treatment for SCID is hematopoietic stem cell transplant (HSCT). In addition, gene therapy serves as an alternative for X-linked and adenosine deaminase (ADA)-deficient SCID if suitable HSC donors are not available (8). SCID patients have a 94% survival rate if they undergo HSCT within the first 3.5 months of life (9). To facilitate timely HSCT, an early diagnosis must be made. However, delay in diagnosis is common due to the lack of awareness of the distinctive presenting features of SCID, such as recurrent and persistent opportunistic infections (2). To date, the only feature that is associated with an earlier diagnosis is a positive family history of infant death due to infection or known SCID in USA (10). In addition, family history of SCID is associated with earlier HSCT before 3.5 months (9, 11). Our present study aimed to identify the clinical features that could help clinicians diagnose SCID earlier by comparing the age and time to the diagnosis of patients with or without certain clinical features.

Materials and Methods

Patient Source and Selection

The Asian Primary Immunodeficiency Network (APIN) is a primary immunodeficiency (PID) referral network established in 2009 by The University of Hong Kong as a platform for consultation and offering free genetic testing for suspected PID in over 70 centers in Asia and Africa. Its database stores clinical information provided by the referring doctors, laboratory results, and genetic test reports (1214). From 2005 to 2016, 147 SCID patients were referred from 23 centers to the APIN for consultation and genetic testing, 42 of whom were reported in our previous study (13). In our study, we included patients with documented age at presentation (AP) and diagnosis. Among them, we selected patients with genetic diagnosis for identifying factors that affected age and time to diagnosis of SCID.

Data Collection

The referring doctors provided the clinical records of patients, together with the laboratory results. Demographic data, clinical presentation, and progress as well as investigation results including ALC and lymphocyte subsets of the patients were recorded. We only considered the clinical features and progression before the diagnosis of SCID was made. We defined AP as the age when the first clinical symptom was documented in the clinical record, age at diagnosis (AD) as the age when clinical diagnosis of SCID was made, and time to diagnosis as the duration between AP and AD. We only considered patients to have certain clinical feature if that feature was stated in the referral summary. We defined recurrent infections as more than one episode of infections affecting similar systems. We considered the infection to be severe if at least one of the following was present: life-threatening complications (such as acute respiratory distress syndrome and sepsis), intensive care unit (ICU) admission, and life support being used (intubation, ventilation, and resuscitation). We defined opportunistic infection as an infection with at least one of the following pathogens was involved: BCG, Candida, Pseudomonas aeruginosa, Acinetobacter baumannii, Pneumocystis jiroveci (PCP), Aspergillus, cytomegalovirus (CMV), and herpes zoster virus. We defined opportunistic infections by Candida if patients were documented to have invasive candidiasis, candidemia or persistent oral candidiasis (15). We presented the ALC recorded at the time of SCID diagnosis. Patients were said to have lymphopenia if ALC below 3 × 109/L as described previously (10). Since there is no universally agreed cutoff of B-cell number to distinguish B+ and B− SCID, we defined the cut-off as 134/μL based on the CD19+ B-cell counts of patients with B+ genotypes (IL2RG, IL7R, and JAK3) and those with B− genotypes (ADA, DCLRE1C, RAG1, and RAG2) (Figure 1).

Figure 1.

Figure 1

CD19+ cell counts of patients with B+ and B− genotypes. B+ genotypes group consisted of CD19+ cell counts of patients with mutations found in IL2RG (n = 43), IL7R (n = 3), and JAK3 (n = 5). B− genotypes group consisted of CD19+ cell counts of patients with mutations found in ADA (n = 1), DCLRE1C (n = 3), RAG1 (n = 3), and RAG2 (n = 2). The cutoff for distinguishing B+ and B− patients was 134 CD19+ cells/μL. Three patients with IL2RG mutations were classified as having B− SCID.

Genetic analysis was performed in the Department of Pediatrics and Adolescent Medicine of the University of Hong Kong using PCR and direct sequencing (Table SE1 in Supplementary Material) (13). Genetic and functional studies on PID, data archival in the APIN database, and DNA storage were approved by the Clinical Research Ethics Review Board of the University of Hong Kong and Queen Mary Hospital (Ref. no. UW 08-301) in accordance with the Declaration of Helsinki, with written informed consent obtained from parents of subjects. HGMD Pro version 2016.4 (16) and Immunodeficiency mutation databases (IDbases) (17) were used to identify unreported mutations. The nomenclatures of cDNA mutations were based on coding region. For each unreported mutation, the population frequency was analyzed by Exome Aggregation Consortium Browser (18). Effects of missense mutations on protein functions were predicted by PANTHER (19), PHD-SNP (20), SIFT (21), SNAP (22), Meta-SNP (23), and PolyPhen2 (24). The protein structure predicted to be involved was identified using NCBI Protein database (25) and UniProt Knowledgebase database (26).

Statistical Analysis

For descriptive statistics, all data were expressed in median and range (month). Univariate analysis was performed using Mann–Whitney U test; multivariate linear regression was performed for all factors that were significant (p < 0.05) in univariate analysis. We defined statistical significance as p < 0.05, and 95% confidence interval did not contain 0 in multivariate analysis. We did not include opportunistic infection group in the multivariate linear regression to avoid multicollinearity.

Patients with missing categorical data such as clinical features were considered to be without the features. Patients with missing numerical data such as ALC were not analyzed when analyzing median and range.

Results

Patients Selection

From 147 SCID patients referred to the APIN, 131 of them had documented AP and diagnosis. Among these patients, 83 of them had genetic diagnosis (Figure 2). Sixteen patients were excluded from the study due to the lack of AP (n = 4), the lack of AD (n = 9), and being diagnosed by screening (n = 3). Among the 16 patients excluded from the study, 11 of them had genetic diagnosis. Altogether, molecular diagnosis of SCID was identified in 94 patients in our cohort.

Figure 2.

Figure 2

Patients selection algorithm in this study. From 147 SCID entries in the Asian Primary Immunodeficiency Network (APIN) database, 131 patients were included in our study and 16 patients were excluded from our study. Three patients were excluded as they were diagnosed by screening either antenatally or at birth. Thirteen patients were excluded due to the lack of age at presentation (n = 4) or the lack of age at diagnosis (n = 9). 1Cordocentesis was performed due to positive family history of SCID, revealed low CD4+ count. 2Complete blood count, lymphocyte subsets, and immunoglobulins measurement were performed in one patient due to positive family history, revealed severe T- and B-cell lymphopenia and low serum IgA and IgM; newborn T-cell receptor excision circle (TREC) screening revealed 0 TREC copy in another patient.

Genetic Mutations in Patients

The genetic mutations of the 83 SCID patients included in our study and 11 SCID patients excluded from our study are shown in Table 1 and Table SE1 in Supplementary Material, respectively. The commonest gene identified was IL2RG (n = 65), followed by RAG1 (n = 7), RAG2 (n = 7), JAK3 (n = 5), DCLRE1C (n = 4), IL7R (n = 3), RFXANK (n = 2), and ADA (n = 1). Eighty-eight different mutations were identified in this study (49 IL2RG mutations, 12 RAG1 mutations, 8 RAG2 mutations, 7 JAK3 mutations, 4 DCLRE1C mutations, 4 IL7R mutations, 2 RFXANK mutations, and 2 ADA mutations). There was no difference in clinical features between X-linked and autosomal recessive SCID patients (Table SE2 in Supplementary Material).

Table 1.

Genetic mutations of SCID patients (n = 83).

No Gene Intron (I)/exon (E) Nucleotide change Predicted change
P001 IL2RG E1 c.3G>T M1I
P002 IL2RG E2 c.127delA T43fsX70
P003 IL2RG E2 c.202G>T E68X
P004a IL2RG E2 c.202G>A E68K
P004b IL2RG E2 c.202G>A E68K
P005 IL2RG E2 c.202G>A E68K
P006 IL2RG E2 c.252C>A N84K
P007 IL2RG I2 g.IVS2−15A>G Predicted aberrant splicing
P008 IL2RG I2 g.IVS2−15A>G Predicted aberrant splicing
P011e IL2RG E3 c.310_311delinsG H104fsX146
P012 IL2RG E3 c.340G>T G114C
P013e IL2RG E3 c.359dupA K120fsX167
P014 IL2RG E3 c.362delA E121fsX146
P015 IL2RG E3 c.365T>C I122T
P016 IL2RG E3 c.365T>C I122T
P017e IL2RG E3 c.371T>C L124P
P018 IL2RG E3 c.376C>T Q126X
P019e IL2RG E3 c.376C>T Q126X
P020 IL2RG E3 c.383T>C F128S
P021 IL2RG E3 c.386T>A V129D
P022 IL2RG E3 c.406_415del R136fsX143
P023e IL2RG E3 c.421delC Q141fsX146
P024 IL2RG I3/E4 junction g.IVS3−2A>T Predicted aberrant splicing
P025e IL2RG E4 c.507delG Q169fsX170
P026 IL2RG E4 c.507delG Q169fsX170
P027e IL2RG E4 c.562C>T Q188X
P028 IL2RG E4 c.562C>T Q188X
P030 IL2RG E5 c.658_659del T220fsX227
P031 IL2RG E5 c.664C>T R222C
P032e IL2RG E5 c.670C>T R224W
P033 IL2RG E5 c.670C>T R224W
P034 IL2RG E5 c.676C>T R226C
P036e IL2RG E5 c.677G>A R226H
P037 IL2RG E5 c.694G>C G232R
P038 IL2RG E5 c.709T>C W237R
P039e IL2RG E5 c.711G>A W237X
P040e IL2RG E5 c.722G>T S241I
P041 IL2RG E5 c.741delG G247fsX272
P042 IL2RG E5 c.741_742insG E248fsX302
P044 IL2RG E6 c.811G>T G271X
P045e IL2RG E6 c.835delG V279fsX293
P046 IL2RG E6/I6 junction c.854G>T R285L
P047e IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P048e IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P049e IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P050e IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P051 IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P052 IL2RG E6/I6 junction c.854G>Af Predicted aberrant splicing
R285Q
P053e IL2RG I6-I7 g.IVS6-72_IVS7-11del Predicted exon 7 deletion
P055 IL2RG I6/E7 junction g.IVS6−2A>C Predicted aberrant splicing
P056 IL2RG I6 g.IVS6+3G>T Predicted aberrant splicing
P057e IL2RG I6 g.IVS6+5G>A Predicted aberrant splicing
P058e IL2RG I6 g.IVS6+5G>A Predicted aberrant splicing
P059 IL2RG E7 c.865C>T R289X
P060 IL2RG E8 c.929G>A W310X
P062 IL2RG E8 c.979_980delinsTT E327L
P063a IL2RG E8 c.982C>T R328X
P064 ADA E7 c.646G>A G216R
E11 c.1018_1019del K340fsX348
P065b DCLRE1C E1-E3 Gross deletion Gross deletion
P066b DCLRE1C E1-E4 Gross deletion Gross deletion
P068e DCLRE1C I3/E4 junction c.IVS3−1G>T I83-G102del
Exon 4 skippeda
E8 c.632G>T G211V
P069e IL7R E1 c.65G>T S22I
E2/I2 junction g.IVS2+2T>A Predicted aberrant splicing
P070b,e IL7R E5 c.562delC L188X
P071b IL7R E5 c.616C>T R206X
P072 JAK3 E2 c.115dupC Q39fsX51
E13 c.1744C>T R582W
P073 JAK3 E3 c.307C>T R103C
E10 c.1333C>T R445X
P074e JAK3 E13 c.1763A>C H588P
P075b,e JAK3 I14 g.IVS14−11G>A 638_639insPPX
c.1914_1915insCCCCCTTAGa
P076c JAK3 E16 c.2062A>T I688F
P077 RAG1 E2 c.994C>T R332X
E2 c.3074dupT L1025fsX1064
P078e RAG1 E2 c.1178delG G393fsX402
E2 c.2095C>T R699W
P079 RAG1 E2 c.1328G>A R443K
E2 c.2486_2490del R829fsX869
P080 RAG1 E2 c.1681C>T R561C
E2 c.2561G>A G854D
P081d RAG1 E2 c.2005G>A E669K
P083 RAG1 E2 c.2324T>A L775Q
E2 c.2918G>A R973H
P084e RAG2 E1/I1 junction c.-28G>C Predicted aberrant splicing
E2 c.358delG V120fsX130
P085b RAG2 E2 c.104G>T G35V
P086b RAG2 E2 c.104G>T G35V
P087 RAG2 E2 c.104G>T G35V
E2 c.475C>T R159C
P088b RAG2 E2 c.218G>A R73H
P089 RAG2 E2 c.442C>T R148X
E2 c.685C>T R229W
P091 RFXANK E3/I3 junction g.IVS3+1delG Predicted aberrant splicing
E5 c.299_300del Q100fsX113
P092b RFXANK E5 c.299_300del Q100fsX113

ADA, adenosine deaminase; DCLRE1C, DNA cross-link repair enzyme 1C; IL2RG, interleukin-2 receptor subunit gamma; IL7R, interleukin-7 receptor subunit alpha; JAK3, Janus kinase 3; RAG, recombinase activating genes; RFXANK, regulatory factor X-associated ankyrin-containing protein.

aFrom RT-PCR results.

bHomozygous mutations.

cP076 was a B+NK− patient with hypogammaglobulinemia (IgG 1.45 g/L, IgA 0.23 g/L, and IgM 0.26 g/L) whose mother was a heterozygous carrier.

dOnly one mutation was found.

ePatients reported in our previous study (13).

fPrevious study reported 854G>A may cause R285Q or skipping of exon 6 (27). P004a and P004b and P063a and P063b (Table SE1 in Supplementary Material) were from the same kindred.

Genetic mutations in all SCID genes were not evenly distributed, and two mutations were seen three or more times in unrelated patients. c.854G>A mutation was seen in six unrelated patients with IL2RG mutation. c.104G>T mutation was observed in three unrelated patients with RAG2 mutation.

Twenty-two C>T or G>A mutations within CpG dinucleotides were documented (8 IL2RG mutations, 5 RAG1 mutations, 4 RAG2 mutations, 3 JAK3 mutations, 1 IL7R mutation, and 1 ADA mutation). These mutations accounted for 25% of all mutations and were involved in 31 patients (18 in IL2RG, 5 in RAG1, 3 in RAG2, 2 in JAK3, 1 in IL7R, and 1 in ADA).

There were 29 unreported mutations identified in our patients, including 23 IL2RG mutations, 3 RAG1 mutations, 1 JAK3 mutation, 1 RAG2 mutation, and 1 RFXANK mutations (Table SE3 in Supplementary Material). Effects of these unreported mutations on protein functions were predicted by multiple tools and are shown in Table SE3 in Supplementary Material.

Characteristics of Patients That Fulfilled Selection Criteria (n = 83)

Characteristics of patients included in our study (n = 131) are shown in Tables 24. For patients that fulfilled selection criteria (n = 83), 88.0% were male (n = 73) and 75.9% were Chinese (n = 63). The median AP was 2 months (0.1–6 months), AD 4 months (0.5–18 months), and time to diagnosis 2 months (0–14 months). Twenty-nine patients (34.9%) had a family history of early infant death (FH), among them one patient had a family history of SCID and one patient had a family history of PID. Parental consanguinity was present in four kindreds. The median ALC was 1.05 × 109/L (0.134−52.2 × 109/L, n = 70) with 88.6% below 3 × 109/L (n = 62). The major immunophenotype was B+ SCID (n = 51) (Tables 2 and 3).

Table 2.

Characteristics of patients included in our study (n = 131) at SCID diagnosis.

With genetic diagnosis Without genetic diagnosis

n = 83 n = 48
Gender Number (%) Number (%)
Male 73 (88.0) 33 (68.8)
Female 10 (12.0) 15 (31.3)
Ethnicity Number (%) Number (%)
Chinese 63 (75.9) 30 (62.5)
Southeast Asian 12 (14.5) 4 (8.3)
 Indonesian 1 (1.2) 0 (0)
 Malay 3 (3.6) 3 (6.3)
 Philippino 1 (1.2) 0 (0)
 Thai 5 (6.0) 1 (2.1)
 Vietnamese 2 (2.4) 0 (0)
Indian 2 (2.4) 9 (18.8)
Algerian 5 (6.0) 0 (0)
Arabian 1 (1.2) 3 (6.3)
Australian 0 (0) 1 (2.1)
Korean 0 (0) 1 (2.1)
Positive family history Number (%) Number (%)
Early infant death 29 (34.9) 13 (27.1)
Consanguinity 4 (4.8) 1 (2.1)
Age in months Median (range) Median (range)
Age at presentation 2 (0.1–6) 2 (0–19)
Age at diagnosis 4 (0.5–18) 4 (0.1–27)
Time to diagnosis 2 (0–14) 2 (0–16)
SCID phenotype Number (%) Number (%)
B+ 51 (61.4) 18 (37.5)
B− 15 (18.1) 24 (50.0)
Others 17 (20.5)a 6 (12.5)b
Median (range) Median (range)
Absolute lymphocyte count (109/L) 1.05 (0.134–52.2)c 0.77 (0.09–13.46)d

aMaternal engraftment (n = 1), unknown (n = 16).

bUnknown (n = 6).

cIn 70 patients.

dIn 44 patients.

Table 4.

Clinical features of patients included in our study (n = 131).

With genetic diagnosis Without genetic diagnosis
n = 83 n = 48

Number (%) Number (%)
Classical SCID triad
Failure to thrive 13 (15.7) 16 (33.3)a
Chronic diarrhea 42 (50.6) 27 (56.3)
Recurrent infections 50 (60.2) 28 (58.3)
Infection by systems
Respiratory infection 61 (73.5)c 34 (70.8)d
Non-bacillus Calmette–Guérin (BCG) skin and soft tissue infection 7 (8.4) 11 (22.9)
Gastrointestinal infection 42 (50.6) 23 (48.9)
Urogenital infection 2 (2.4) 1 (2.1)
Musculoskeletal infection 3 (3.6) 1 (2.1)
Central nervous system infection 1 (1.2) 1 (2.1)
Sepsis 18 (21.7) 8 (16.7)
Severe infections 39 (47.0) 26 (54.2)
Intensive care unit admission 24 (28.9) 14 (29.2)
Life support 26 (31.3) 14 (29.2)
 Intubation and ventilation 21 (25.3) 8 (16.7)
 Resuscitation and/or inotrope support 5 (6.0) 9 (18.8)
Life-threatening complication 40 (48.2) 18 (37.5)
 Sepsis 18 (21.7) 8 (16.7)
 Respiratory distress/failure 26 (31.3) 13 (27.1)
 Acute heart failure 2 (2.4) 1 (1.2)
Opportunistic infections 50 (60.2) 28 (58.3)
Bacterial 8 (9.6) 1 (2.1)
Pseudomonas aeruginosa 6 (7.2) 0 (0)
Acinetobacter baumanii 4 (4.8) 1 (2.1)
Viral 9 (10.8) 12 (25.0)
 Cytomegalovirus (CMV) 8 (9.6)e 12 (25.0)b
 Herpes zoster 1 (1.2) 0 (0)
Bacillus Calmette–Guérin (BCG) infection 19 (22.9)f 8 (16.7)
 Local 8 (9.6) 2 (4.2)
 Regional 2 (2.4) 1 (2.1)
 Disseminated 9 (10.8) 5 (10.4)
Candidiasis 27 (32.5)g 16 (33.3)
 Persistent oral thrush 22 (26.5) 10 (20.8)
 Gastrointestinal tract infection 3 (3.6) 2 (4.2)
 Candidemia 2 (2.4) 4 (8.3)
Fungal 3 (3.6) 2 (4.2)
Pneumocystis jiroveci 2 (2.4) 1 (2.1)
 Aspergillosis 1 (1.2) 1 (2.1)
Hepatosplenomegaly 12 (14.5) 9 (18.8)

ap = 0.0189.

bp = 0.0185.

cA total of 53 patients with genetic diagnosis had pneumonia (63.9%).

dA total of 32 patients without genetic diagnosis had pneumonia (66.7%).

eThe median age for CMV infection documented was 2.25 months (n = 8).

fThe median age for BCG infection documented was 4 months (n = 14).

gThe median age for candidiasis documented was 3 months (n = 25).

Table 3.

Lymphocyte subset for patients included in our study (n = 131).

Patient Mutation gene ALC (×109/L) CD3+ cells/μL (%) CD19+ cells/μL (%) CD16/56+ cells/μL (%)
B+ SCID
P006 IL2RG 0.4 9.2 (2.3) 385.6 (96.4) 2.4 (0.6)
P008 IL2RG 0.95 0 (0) 931 (98) 9.5 (1)
P011 IL2RG 1.16 3.48 (0.3) 972 (83.8) 2.3 (0.2)
P013 IL2RG 0.31 0 (0) 270 (87) 0 (0)
P014 IL2RG 2.93 468 (16) 2,344 (80) 58.6 (2)
P015 IL2RG 0.51 0 (0) 459 (90) 10.2 (2)
P017 IL2RG 0.7 0.7 (0.1) 663 (94.7) 36.4 (5.2)
P018 IL2RG 1 20 (2) 890 (89) 0 (0)
P019 IL2RG 2.63 26.3 (1) 2,525 (96) 26.3 (1)
P020 IL2RG 0.38 22.8 (6) 345.8 (91) 0 (0)
P021b IL2RG 1.66 596 (35.9) 1,061 (63.9) 2 (0.12)
P022 IL2RG 0.33 7.59 (2.3) 313.5 (95) 6.6 (2)
P024b IL2RG 3.43 504 (14.7) 2,867 (83.6) 58.3 (1.7)
P025 IL2RG 1.4 0 (0) 1,302 (93) 42 (3)
P026 IL2RG 0.33 16.5 (5) 290.4 (88) 9.9 (3)
P027 IL2RG 1.1 5.5 (0.5) 1,022 (92.9) 14.3 (1.3)
P028 IL2RG 5 4,600 (92) 300 (6) 100 (2)
P030 IL2RG 0.94 16 (1.7) 620.4 (66) 192.7 (20.5)
P031 IL2RG 5.1 948 (18.6) 3,042 (59.7) 928.7 (18.2)
P032 IL2RG 1.1 11 (1) 979 (89) 110 (10)
P033 IL2RG 0.99 5 (0.5) 585.1 (59.1) 17.8 (1.8)
P034 IL2RG 1.34 0 (0) 1,112 (83) 160.8 (12)
P036 IL2RG 1.11 11.1 (1) 455.1 (41) 577 (52)
P038 IL2RG 0.6 240 (40) 324 (54) 33 (5.5)
P039 IL2RG 1.72 0 (0) 1,170 (68) 498.8 (29)
P041 IL2RG 0.62 12.4 (2) 545.6 (88) 37.2 (6)
P044 IL2RG 0.9 0 (0) 846 (94) 18 (2)
P045 IL2RG 1.84 0 (0) 1,748 (95) 73.6 (4)
P047 IL2RG 1.41 155.1 (11) 1,197 (84.9) 18.3 (1.3)
P048 IL2RG 4.94 0 (0) 4,841 (98) 98.8 (2)
P049 IL2RG 2.1 0 (0) 2,079 (99) 0 (0)
P050 IL2RG 0.53 5.3 (1) 424 (80) 21.2 (4)
P051 IL2RG 1.1 0 (0) 1,067 (97) 11 (1)
P052 IL2RG 1.86 223.2 (12) 1,600 (86) 0 (0)
P053 IL2RG 1 52 (5.2) 892 (89.2) N/A (N/A)
P055 IL2RG 0.9 9 (1) 828 (92) 9 (1)
P056 IL2RG 1.3 1 (0.08) 1,282 (98.6) 9.6 (0.74)
P058 IL2RG 1.3 0 (0) 611 (47) 18.2 (1.4)
P059 IL2RG 1.18 0 (0) 1,133 (96) 35.4 (3)
P060 IL2RG 1.5 45 (3) 1,350 (90) 30 (2)
P063a IL2RG 0.62 61.4 (9.9) 484.2 (78.1) 46.5 (7.5)
P069 IL7R 1.89 183.3 (9.7) 1,111 (58.8) 565.1 (29.9)
P070 IL7R 1.21 147.6 (12.2) 756.3 (62.5) 410.2 (33.9)
P071 IL7R 0.785 1.6 (0.2) 148.4 (18.9) 433.3 (55.2)
P072 JAK3 2.52 1,738 (69) 730.8 (29) 0 (0)
P073 JAK3 0.47 4.7 (1) 437.1 (93) N/A (N/A)
P074 JAK3 0.35 91 (26) 196 (56) N/A (N/A)
P075 JAK3 0.49 6.4 (1.3) 266.1 (54.3) 19.6 (4)
P076 JAK3 1.5 12.6 (0.84) 1,377 (91.77) 54.5 (3.63)
P078 RAG1 7.64 3,965 (51.9) 267.4 (3.5) 3,705 (48.5)
P091 RFXANK 1.59 624.9 (39.3) 936.5 (58.9) 47.7 (3)
P094 N/A 2.06 195.7 (9.5) 1,788 (86.8) 76.2 (3.7)
P098 N/A 1.23 764.2 (62.13) 156.9 (12.76) 263.1 (21.39)
P099 N/A 13.46 9,826 (73) 1,346 (10) 1,750 (13)
P109 N/A 0.88 295.7 (33.6) 460.2 (52.3) 89.5 (10.2)
P110 N/A 2.06 68 (3.3) 1,593 (77.3) 345.7 (16.8)
P111 N/A 1.46 18.3 (1.25) 1,387 (95) 6.6 (0.45)
P112 N/A 2.42 217.8 (9) 1,500 (62) 532.4 (22)
P115 N/A 1.84 18.4 (1) 1,472 (80) 294.4 (16)
P116 N/A 1.3 26 (2) 1,040 (80) 130 (10)
P117 N/A 2.1 396.9 (18.9) 573.3 (27.3) 136.5 (6.5)
P120 N/A 1.09 21.8 (2) 1,030 (94.5) 3.3 (0.3)
P121 N/A 0.5 20 (4) 245 (49) 205 (41)
P122 N/A 0.41 32.8 (8) 278.8 (68) 86.1 (21)
P123b N/A 1.28 65.3 (5.1) 833.3 (65.1) 381.4 (29.8)
P124 N/A 0.8 15.2 (1.9) 724 (90.5) 43.2 (5.4)
P126 N/A 0.84 342.7 (40.8) 207.5 (24.7) 197.4 (23.5)
P128 N/A 3.5 2,485 (71) 455 (13) 455 (13)
P137 N/A 0.9 9.9 (1.1) 136.8 (15.2) 419.4 (46.6)
B− SCID
P001 IL2RG 0.14 0 (0) 70 (50) 1.4 (1)
P002 IL2RG 0.67 636.5 (95) 13.4 (2) 0 (0)
P003 IL2RG 3.6 3,456 (96) 0 (0) N/A (N/A)
P005 IL2RG 0.18 7.2 (4) 3.6 (2) 145.8 (81)
P064 ADA 0.21 4 (1.9) 1 (0.48) 16.8 (8)
P065 DCLRE1C 0.65 110.5 (17) 26 (4) 78 (12)
P066 DCLRE1C 1.2 36 (3) 24 (2) 1,080 (90)
P068 DCLRE1C 0.72 7.2 (1) 0.72 (0.1) 672.5 (93.4)
P079 RAG1 0.96 144 (15) 1.9 (0.2) 796.8 (83)
P080 RAG1 0.134 132 (98.6) 0.04 (0.03) 1.5 (1.1)
P083 RAG1 0.34 80.6 (23.7) 3.1 (0.9) 190.1 (55.9)
P084 RAG2 0.74 7.4 (1) 7.4 (1) 666 (90)
P087 RAG2 2.55 2.6 (0.1) 132.6 (5.2) 2,020 (79.2)
P088 RAG2 28.36 26,772 (94.4) 0 (0) 623.9 (2.2)
P092 RFXANK 1.019 276.1 (27.1) 19.4 (1.9) 25.5 (2.5)
P093 N/A 0.31 N/A (N/A) 2 (0.65) 120.9 (39)
P095 N/A 3.38 3,191 (94.4) 33.8 (1) 33.8 (1)
P097 N/A 2.49 2,366 (95) 18.9 (0.76) 49.8 (2)
P100 N/A 0.489 477.8 (97.7) 2.9 (0.6) 4.9 (1)
P101 N/A 0.242 15 (6.19) 2.9 (1.2) 206.4 (85.3)
P102 N/A 0.09 41.1 (45.7) 1.4 (1.6) 19.5 (21.7)
P103 N/A 1.8 1,499 (83.3) 3.6 (0.2) 257.4 (14.3)
P104 N/A 0.138 26.2 (19) 1.4 (1) 93.8 (68)
P105 N/A 0.72 144 (20) 0.72 (0.1) 537.1 (74.6)
P106 N/A 0.42 408.2 (97.2) 1.3 (0.3) 4.6 (1.1)
P107 N/A 0.65 76.7 (11.8) 29.3 (4.5) 490.8 (75.5)
P108 N/A 0.8 40 (5) 14.4 (1.8) 656 (82)
P114 N/A 0.59 11.8 (2) 15.9 (2.7) 472 (80)
P118 N/A 0.19 0 (0) 39.9 (21) 0.38 (0.2)
P125 N/A 0.84 579.6 (69) 100.8 (12) 134.4 (16)
P127 N/A 0.53 312.2 (58.9) 73.1 (13.8) 19.6 (3.7)
P130 N/A 0.29 70.8 (24.4) 45.8 (15.8) 150.8 (52)
P131 N/A 0.8 16 (2) 0 (0) 768 (96)
P132 N/A 0.74 583.1 (78.8) 17.8 (2.4) 96.2 (13)
P134 N/A 0.7 539 (77) 0 (0) 1.1 (0.16)
P135 N/A 1.03 20.6 (2) 30.9 (3) 875.5 (85)
P136 N/A 0.28 254.8 (91) 2.8 (1) 19.6 (7)
P138 N/A 0.22 72.6 (33) 2.2 (1) 129.8 (59)
P139 N/A 0.1 42.8 (42.8) 4.1 (4.1) 50 (50)

Others

Maternal engraftment
P077 RAG1 52.23 49,619 (95) 0 (0) 2,089 (4)
Unknown
P004a IL2RG 0.64 0 (0) N/Aa N/Aa
P004b IL2RG N/A N/A (2) N/A (85) N/A (10)
P007 IL2RG N/A N/A (0.2) N/A (86.7) N/A (6.7)
P012 IL2RG N/A N/A (2) N/A (95) N/A (0)
P016 IL2RG N/A N/A (N/A) N/A (N/A) N/A (N/A)
P023 IL2RG 0.5 N/A (N/A) N/A (N/A) N/A (N/A)
P037 IL2RG 1.6 N/A (N/A) N/A (N/A) N/A (N/A)
P040 IL2RG N/A N/A (16) N/A (82) N/A (0)
P042 IL2RG N/A N/A (2) N/A (95) N/A (1)
P046 IL2RG N/A N/A (0) N/A (93) N/A (2)
P057 IL2RG N/A N/A (0) N/A (89) N/A (0)
P062 IL2RG 5.4 N/A (N/A) N/A (N/A) N/A (N/A)
P081 RAG1 N/A N/A (1.5) N/A (0.52) N/A (74.1)
P085 RAG2 N/A N/A (13) N/A (0.1) N/A (24)
P086 RAG2 N/A N/A (0.67) N/A (0) N/A (76)
P089 RAG2 N/A N/A (N/A) N/A (N/A) N/A (N/A)
P096 N/A 0.26 N/A (N/A) N/A (N/A) N/A (N/A)
P113 N/A N/A N/A (1) N/A (87) N/A (4)
P119 N/A N/A N/A (3) N/A (67.5) N/A (25.4)
P129 N/A 0.22 N/A (N/A) N/A (N/A) N/A (N/A)
P133 N/A 0.6 N/A (N/A) N/A (N/A) N/A (N/A)
P140 N/A N/A N/A (2.8) N/A (0.6) N/A (90)

B+ SCID was defined as having ≥134 CD19+ cells/μL and B− SCID was defined as having <134 CD19+ cells/μL. ALC, absolute lymphocyte count; N/A, not available.

aMedical record documented as “raised”.

bALC was not provided, derived by summation of CD3+ cells, CD19+ cells, and CD16/56+ cells, in P024 the ALC was documented as 2.7 × 109/L in separate test.

50.6% of patients presented with chronic diarrhea (n = 42) and 60.2% of patients recurrent infections (n = 50). The commonest site of infection was the respiratory system (n = 61), followed by gastrointestinal system (n = 42). 47.0% of infections were severe (n = 39).

Fifty patients developed opportunistic infection (60.2%). The commonest opportunistic infection was candidiasis (n = 27), followed by BCG infection (n = 19) and viral infection (n = 9). The median age for candidiasis documented was 3 months, the median age for BCG infection was 4 months, and the median age for CMV infection was 2.25 months.

For patients included in our study, clinical features were compared between those with (n = 83) and without genetic diagnosis (n = 48). Patients without genetic diagnosis had higher frequency of FTT (33.3 versus 15.7%, p = 0.0189) and CMV infections (25.0 versus 9.6%, p = 0.0185) (Table 4).

For patients with documented ALC (n = 114), 107 of them (93.9%) had at least one of the following four clinical features: FH, candidiasis, BCG infection, and ALC below 3 × 109/L. 65 of them (57.0%) had at least two of the four clinical features mentioned.

FH and Pneumonia Were Associated with Earlier AP

Factors that were found to significantly affect AP, AD, and time to diagnosis are shown in Tables 5 and 6.

Table 5.

Univariate analysis of features that affect age at presentation (AP), age at diagnosis, and time to diagnosis in patients fulfilled selection criteria (n = 83).

Features Median AP (months) when
Difference in months (Group A–Group B) p-Value
Feature present (Group A) Feature absent (Group B)
FH 1 2 −1 0.002
Candidiasis 2 2 0 0.664
Bacillus Calmette–Guérin (BCG) 2 2 0 0.291
CMV 1 2 −1 0.280
FTT 2 2 0 0.954
Chronic diarrhea 2 2 0 0.778
Recurrent infections 2 3 −1 0.008
Severe infections 2 2 0 0.813
Pneumonia 2 3 −1 0.003
Hepatosplenomegaly 2.25 2 0.25 0.347
X-linked SCID 2 2 0 0.057
Low ALCa 2 2.25 −0.25 0.771

Features Median age at diagnosis (months) when
Difference in months (Group C–Group D) p-Value
Feature present (Group C) Feature absent (Group D)

FH 3 5 −2 0.008
Candidiasis 6 4 2 0.008
BCG 6 4 2 0.005
CMV 3 4 −1 0.025
FTT 7 4 3 0.038
Chronic diarrhea 4 4.5 −0.5 0.949
Recurrent infections 5 4 1 0.241
Severe infections 4 5 −1 0.476
Pneumonia 4 5 −1 0.111
Hepatosplenomegaly 4 4 0 0.544
X-linked SCID 4 3.5 0.5 0.689
Low ALCa 4 6.5 −2.5 0.086

Features Median time to diagnosis (months) when
Difference in months (Group E–Group F) p-Value
Feature present (Group E) Feature absent (Group F)

FH 2 2 0 0.494
Candidiasis 2.5 1.95 0.55 0.003
BCG 3 2 1 0.052
CMV 1.25 2 −0.75 0.155
FTT 4 2 2 0.104
Chronic diarrhea 1.15 2 −0.85 0.617
Recurrent infections 2.5 1 1.5 <0.001
Severe infections 2 2 0 0.565
Pneumonia 2 1.75 0.25 0.382
Hepatosplenomegaly 1.5 2 −0.5 0.217
X-linked SCID 2 2 0 0.569
Low ALCa 2 4.5 −2.5 0.124

aDefined as ALC below 3 × 109/L.

FH, family history of early infant death; CMV, cytomegalovirus infection; FTT, failure to thrive, ALC, absolute lymphocyte count.

Table 6.

Multivariate linear regression of features that affect age at presentation (AP), age at diagnosis (AD), and time to diagnosis in patients fulfilled selection criteria (n = 83).

Features Regression coefficient (months) p-Value 95% CI
AP
FH −0.884 0.005 −1.499 to −0.269
Recurrent infections −0.541 0.086 −1.161 to 0.078
Pneumonia −0.863 0.009 −1.504 to −0.221
AD
FH −1.86 0.007 −3.189 to −0.529
Candidiasis 2.21 0.002 0.858 to 3.555
Bacillus Calmette–Guérin 1.11 0.141 −0.375 to 2.595
CMV −1.58 0.147 −3.727 to 0.569
FTT 1.15 0.190 −0.584 to 2.886
Time to diagnosis
Candidiasis 1.511 0.018 0.267 to 2.754
Recurrent infections 1.845 0.003 0.655 to 3.036

FH, family history of early infant death; CMV, cytomegalovirus infection; FTT, failure to thrive; 95% CI, 95% confidence interval.

In univariate analysis, FH, pneumonia, and recurrent infections were associated with earlier AP (FH by 1 month, p = 0.002; pneumonia by 1 month, p = 0.003; recurrent infections by 1 month, p = 0.008). Upon multivariate analysis, only FH and pneumonia were associated with earlier AP (FH by 0.884 month, p = 0.005; pneumonia by 0.863 month, p = 0.009).

FH Was Associated with Earlier AD

In univariate analysis, FH and CMV infections were associated with an earlier AD (FH by 2 months, p = 0.008; CMV by 1 month, p = 0.025). Upon multivariate analysis, only FH was associated with earlier AD (by 1.86 months, p = 0.007).

Candidiasis and Opportunistic Infections Were Associated with Later AD

In univariate analysis, candidiasis, FTT, opportunistic infections, and BCG infection were associated with a later AD (candidiasis by 2 months, p = 0.008; FTT by 3 months, p = 0.038; opportunistic infections by 1 month, p = 0.018; BCG by 2 months, p = 0.005). Upon multivariate analysis, only candidiasis was associated with later AD (by 2.21 months, p = 0.002).

Candidiasis, Opportunistic Infections, and Recurrent Infections Were Associated with Longer Time to Diagnosis

Candidiasis, opportunistic infections, and recurrent infections were shown to be associated with longer time to diagnosis (candidiasis by 0.55 month, p = 0.003; opportunistic infections by 1 month, p = 0.005; recurrent infections by 1.5 months, p < 0.001). Upon multivariate analysis, both candidiasis and recurrent infections were associated with longer time to diagnosis (candidiasis by 1.51 months, p = 0.018; recurrent infections by 1.85 months, p = 0.003).

Other Features Were Not Significantly Associated with AD and Time to Diagnosis

Analysis of chronic diarrhea, pneumonia, hepatosplenomegaly, severe infections, and lymphopenia revealed no association with AD and time to diagnosis. There was no difference between X-linked and autosomal recessive forms of SCID in AP, AD, and time to diagnosis.

Discussion

We found family history of early infant death was associated with earlier AP and earlier AD but not shorter time to diagnosis. Therefore, the earlier AD could be due to the heightened alertness of family with such history so that medical attention was sought earlier, rather than prompting clinicians in making quicker SCID diagnosis. The association between positive family histories and earlier AD was reported by studies in USA and France (10, 28), but they did not investigate whether the positive family history shortened the time to diagnosis. Moreover, they did not investigate whether presence of family history of early infant death alone is associated with an earlier AD. Previous studies reported 16–60% of patients with positive family histories compared to that of 32% in our study; however, the definition of family history differs between studies (Table 7). Our findings suggested that the family history of early infant death was valuable in alerting families but not clinicians who failed to recognize this clue as the time to diagnosis remained the same regardless of the presence of family history of early infant death.

Table 7.

Comparison with previous SCID studies.

Cohort n Origin Duration AP (months) AD (months) Genotype (%)
ALC (×109/L) Present in cases (%)
IL2RG Other Unknown FH Candidiasis BCG infection
Our study 131 Asia 2005–2016 2 (0–19)a 4 (0.1–27)a 57 (44) 26 (20) 48 (37) 0.975 (0.09–52.20)a 42/131 (32)f 43/131 (33) 27/131 (21)e
Stephan et al. (28) 117 France 1970–1992 3 (0–19)c 4.6 (0–27)c 0 (0) 0 (0) 117 (100) 1.608 (0–30)c 70/117 (60) 33/117 (28) 10/28 (36)e
Mazzucchelli et al. (29) 70 Brazil 1996–2011 2 (0–19)a 8 (0–22)a 0 (0) 0 (0) 70 (100) N/A 19/70 (27)g 29/64 (45) 39/69 (57)e
Yeganeh et al. (30) 40 Iran 1999–2007 2.26 (±0.43)b 5 (±0.67)b 0 (0) 0 (0) 40 (100) 1.26a 20/40 (50)h 23/40 (58) 18/40 (45)e
Saleem et al. (31) 13 Pakistan 2006–2011 N/A 5 (1.23–8.93)a 0 (0) 0 (0) 13 (100) 0.41 (0.17–2.28)a 7/13 (54)f N/A N/Ae

McWilliams et al. (10) 172 USA 1982–2013 N/A 4.87 (0–18)b 77 (45) 91 (53) 4 (2) 0.43 (±1.28)b 63/172 (37)h 74/172 (43) 2/172 (1)
Dvorak et al. (32) 50 North America 2010–2012 N/A 1.13 (0–10.13)d 20 (40) 27 (54) 3 (6) 1.22 (0.02–10.72)a 12/50 (24)i 8/50 (16) 0/0 (0)
Rozmus et al. (33) 40 Canada 2004–2010 N/A 4.2 (0–19.4)c 4 (10) 16 (40) 20 (50) 1.13 (0.05–14.04)a 20/39 (51)j 8/39 (21) 0/0 (0)

AP, age at presentation; AD, age at diagnosis; ALC, absolute lymphocyte count; FH, positive family history.

aMedian (range).

bMean (SD).

cMean (range).

dTypical SCID (n = 37) only.

eWith universal BCG vaccination at birth.

fFH of early infant death.

gSuggestive or confirmed FH of SCID.

hFH of early infant death due to infection or known SCID.

iFH of immunodeficiency.

jFH of SCID and/or infant death and consanguinity.

We found candidiasis was associated with later AD and longer time to diagnosis. The median age of candidiasis documented was 3 months, and the median AD of SCID for patients with candidiasis was 6 months. Therefore, clinicians required 3 months to diagnose SCID after candidiasis was first documented. This suggested that candidiasis was an overlooked feature by clinicians in Asia. Other studies reported similar percentage at candidiasis in SCID patients but no report of association between candidiasis and AD (Table 7). Although oral candidiasis is relatively common in infants under 6 months old; however, persistent, recurrent, or invasive candidiasis warrants investigation for underlying immunodeficiencies in particular SCID (15). Our finding suggested that candidiasis may be useful as a clue for earlier diagnosis since the median age of candidiasis documented was 3 months, which was earlier than the optimal time for HSCT at 3.5 months (9, 11).

We were surprised to find that BCG infection was not associated with AD and time to diagnosis. This could be due to the relatively low frequency of patients with BCG infections (21%) identified in our study, which was at a lower frequency when compared to that of 45–57% reported previously (6, 29, 30). The population coverage, immunization schedules, and virulence of BCG in countries and regions included in our study were comparable to that in Brazil and Iran (Table SE5 in Supplementary Material) (29, 3439); therefore, the above factors of BCG policies could not account for the discrepancy in the frequency of BCG complications between our study and that from Brazil and Iran. In addition, the onset of BCG complication in our study at 4 months old was comparable to that in Brazil at 3.7 months old (29). The median AD of SCID in our study was 4 months, which was earlier than the 8 months in Brazil and 5 months in Iran, suggesting that the lower frequency of BCG infections in our study (21%) than that in Brazil (57%) and Iran (45%) (Table 7) could be due to earlier diagnosis of SCID in our study.

The median age for BCG infection documented in our patients was 4 months, which was beyond the optimal time for HSCT. Our findings were in line with a previous report in which 74% of 349 BCG-vaccinated SCID patients developed BCG infection at or after 4 months of age (6). Therefore, despite BCG infections being useful clinical features of SCID as SCID patients have approximately 400-fold increase in risk of having localized BCG complication and 33,000-fold increase in risk of having disseminated complications (6), noticing BCG infection had little value in alerting clinicians to make a timely diagnosis of SCID for optimal HSCT, which should be before 3.5 months (9, 11).

We found that opportunistic infections were associated with later AD, while recurrent infections and opportunistic infections were associated with longer time to diagnosis. Therefore, such clinical features were likely the consequences of delay in the diagnosis of SCID, reflecting that clinicians in Asia were unable to recognize these as SCID features.

We found that pneumonia was associated with an earlier AP but did not affect AD and time to diagnosis. Therefore, parents may perceive pneumonia as a severe medical condition and then brought their children to seek medical care earlier. However, pneumonia also commonly affects children without SCID in Asia (4042), and clinicians are not alerted to the possible diagnosis of SCID.

Chronic diarrhea, severe infections, and ALC below 3 × 109/L were not associated with AD and time to diagnosis, likely due to the distributions of the AD and the time to diagnosis that were quite wide in patients with these features (Figure S1 in Supplementary Material). In addition, chronic diarrhea is common in Southeast Asia and Western Pacific region (40); thus, it may not be a useful differentiating feature for patients with SCID as compared to those without. CMV infections did not affect AD and time to diagnosis as they were documented in small number of patients in our study (n = 8). The low rate of documented CMV infections may be due to the lack of diagnostic capacity (43, 44).

This study presented the largest collection of SCID patients in China and Southeast Asia with 147 patients, including 94 SCID patients with genetic diagnosis. The median AD was 4 months, which was comparable to other cohorts in the world, given no newborn screening of TREC was performed (Table 7) (10, 2833); however, it was later than the optimal time for HSCT.

The commonest SCID gene found to be mutated in our patients was IL2RG because of the low consanguinity rate in our population (45) as well as near absence of newborn screening in Asia. Mutations in IL2RG were unevenly distributed. Exons 3 and 5 of IL2RG were common sites for mutation, accounting for 45% of all IL2RG mutations (Table 1; Table SE1 in Supplementary Material) and 48% of all unreported IL2RG mutations (Table SE3 in Supplementary Material), which was comparable with previous study (46). Five mutation hotspots, namely cDNA 670, 676, 677, 854, and 865, were identified previously and accounted for 29% of all IL2RG mutations in one study (46). Mutations in these hotspots collectively accounted for 27% of IL2RG mutations in our study. Majority of the mutations in these hotspots involved either C>T or G>A mutations in CpG dinucleotides. The mutation frequency of the C nucleotides in CpGs is 10–50 times higher compared to any other bases (47). This is commonly thought to be due to the methylation and subsequently deamination of cytosine to form thymidine in CpG (48, 49). Apart from the mentioned hotspots, we identified 16 additional point mutations in all SCID genes involving such mechanism, suggesting that cytosine methylation and deamination to thymidine in CpG dinucleotide is a relatively common mechanism causing mutations in SCID genes.

Four patients with mutations in IL2RG were classified as having B− SCID with CD19+ B cells ranging from 0 to 70/μL (Table 3). The four patients had typical SCID presentations (Table SE4 in Supplementary Material). One patient was screened for DCLRE1C, RAG1, and RAG2 due to his B− phenotype, but no mutation found. Patients suffering from X-linked SCID but with T-B− phenotype have been described previously (28). Patients with documented IL2RG mutations but with T-B+NK+ phenotype were also described previously (5052). Many possible mechanisms can lead to atypical SCID immunophenotypes, including concurrent mutations in other SCID genes, modifier gene(s), and mutations, that lead to sparing or disrupting developments of other lineages of lymphocytes. In addition, one patient with mutations in RAG1 was classified as having B+ SCID with 267.4 CD19+ B cell/μL (Table 3). He likely had either Omenn syndrome or maternal engraftment due to his T+B+NK+ immunophenotype as well as his clinical presentation of severe eczema and eosinophilia (Table 3; Table SE4 in Supplementary Material). The T+B+NK+ immunophenotype of this patient may be explained by his missense mutation (c.2095C>T; p.R699W). This hypomorphic mutation results in a mutant RAG1 enzyme with 19.3% residual recombinase activity (53), thus allowing the generation of B cells in this patient. These cases in our study as well as previous reports demonstrated the imperfect correlation of genotype–immunophenotype in SCID patients.

We reported two patients (P091 and P092) with RFXANK mutations, with one (P092) reported previously in Chinese literature (54). These patients were the only two with confirmed RFXANK mutations reported in Asia. RFXANK mutation causes bare lymphocyte syndrome type 2B (55), commonly observed in North Africa (56) and sometimes in other places such as France and Spain (57). MHC class II deficiency accounted for 32% of all forms of SCID and their variants in North Africa (5862), while it accounted for 1.4% of all SCID in Asia. Such discrepancy could be explained by the higher consanguinity rate of 50% in North Africa (63) compared to that of less than 10% in Asia (45), as well as presence of founder mutations in North Africa (56, 64). These patients present with features of typical SCID and frequently with sclerosing cholangitis (56, 65). However, they have normal TREC level and cannot be identified by newborn screening (5, 66).

The care of patients with SCID in Asia is still at an early phase of development, as reflected by delay in diagnosis and suboptimal management with no easy access to HSCT (12, 14). Eighty-one of the 83 patients were the first member of their respective families to be diagnosed genetically with SCID, thus explaining the relative lack of family history of SCID in our study. For genetic counseling, we offered testing for family members of SCID patients including prenatal and newborn screening on siblings of six index patients as well as carrier screening for parents, siblings, and maternal aunts of 56 index patients (Table SE6 in Supplementary Material). Unfortunately, there is still a relative lack of clinical genetic service in Asia.

The median ALC in all studies including ours was below 3 × 109/L, and reaffirming lymphopenia is a feature commonly seen in SCID patients (Table 7). However, clinicians failed to act on this critical clue as lymphopenia did not affect the AD or time to diagnosis. Since 1994, many reports have emphasized the importance of low ALC in alerting clinicians regarding SCID (6770), but sadly clinicians to this date still failed to appreciate the value of low ALC for the diagnosis of SCID.

In this study, we identified that FH, candidiasis, and ALC below 3 × 109/L were overlooked clinical features prompting the diagnosis of SCID. In addition, BCG infections were useful clinical features as they were the second most common opportunistic infections in our SCID patients. Ninety-four percent of patients in our study had at least one of the following four features: FH, candidiasis, BCG infections, and ALC below 3 × 109/L. Therefore, we suggest a simple guideline mandating that clinicians should order lymphocyte subset analysis for infants with any one of the following four features: FH, candidiasis, BCG infections, and ALC below 3 × 109/L.

Failure to diagnose SCID in time will lead to delay in HSCT, leading to economic losses in addition to poor outcome. Study has shown that the mean total hospital charges in patients who had HSCT after 3.5 months were four times greater than those before 3.5 months (71). Since all the clinical features we analyzed failed to help clinicians in making earlier SCID diagnosis, newborn screening is the only solution for making early enough diagnosis of SCID for timely HSCT in Asia.

Our retrospective case-series relied on reports made by referring doctors instead of analyzing original charts and results; therefore, underreport of clinical features was possible. In addition, our handling of missing data tends to underestimate the strength of association of clinical features with AD and time to diagnosis.

In conclusion, clinicians failed to recognize typical clinical features of SCID to shorten the time to diagnosis. There is an urgent unmet need to educate clinicians in Asia on SCID. Ultimately, the only solution for early diagnosis of and timely HSCT for patients with SCID is newborn screening.

Ethics Statement

Genetic and functional studies on PID, data archival in the APIN database, and DNA storage were approved by the Clinical Research Ethics Review Board of the University of Hong Kong and Queen Mary Hospital (Ref. no. UW 08-301).

Author Contributions

ADL, PL, and YL designed the study; ADL and YL wrote the manuscript with extensive appraisal from PL, K-WC, and HM; YL, K-WC, WW, and ADL analyzed the data; K-WC, WY, and WT performed the genetic and immunological studies; PL, HM, YL, XC, T-XC, JH, NK, DS, YT, YX, LJ, WL, OJ, TD, AG, SS, AR, AHL, ACL, LS, TN, TC, YC, ZL, TML, NL, BL, QL, DR, M-RB, M-KT, MA, XW, CX, HY, H-HY, TLL, FY, PC, and MH contributed clinical data and took care of patients in this study. PL and YL established the Asian Primary Immunodeficiency Network (APIN).

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This work was supported by the Hong Kong Society for Relief of Disabled Children; the Health and Medical Research Fund (01120846); and grant from Shenzhen Development and Reform Commission ([2015]164).

Supplementary Material

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00808/full#supplementary-material.

Figure S1

Distribution of age at diagnosis and time to diagnosis of patients with genetic diagnosis (n = 83). Distribution of age at diagnosis of patients with chronic diarrhea (A), severe infections (B), and lymphopenia (C) and distribution of time to diagnosis of patients with chronic diarrhea (D) and lymphopenia (E).

Abbreviations

ADA, adenosine deaminase gene; ALC, absolute lymphocyte count; AD, age at diagnosis; AP, age at presentation; APIN, Asian Primary Immunodeficiency Network; BCG, bacillus Calmette–Guérin; CMV, cytomegalovirus; DCLRE1C, DNA cross-link repair enzyme 1C (Artemis); FH, family history of early infant death; FN3, fibronectin type-III; FTT, failure to thrive; HSCT, hematopoietic stem cell transplant; ICU, intensive care unit; IL2RG, IL-2 receptor gamma chain; IL7R, IL-7 receptor alpha chain; JAK 3, janus kinase 3; PCP, Pneumocystis jiroveci; PID, primary immunodeficiency; RAG1, recombinase activating gene 1; RAG2, recombinase activating gene 2; RFXANK, regulatory factor X associated ankyrin containing protein; SCID, severe combined immunodeficiency; TREC, T-cell receptor excision circle.

References

  • 1.Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol (2015) 35(8):696–726. 10.1007/s10875-015-0201-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers (2015) 1:15061. 10.1038/nrdp.2015.61 [DOI] [PubMed] [Google Scholar]
  • 3.Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol (2015) 39(3):194–205. 10.1053/j.semperi.2015.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr (1997) 130(3):378–87. 10.1016/S0022-3476(97)70199-9 [DOI] [PubMed] [Google Scholar]
  • 5.Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA (2014) 312(7):729–38. Erratum in: JAMA (2014) 312(20):2169. 10.1001/jama.2014.9132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol (2014) 133(4):1134–41. Erratum in: J Allergy Clin Immunol (2014) 134(1):244. 10.1016/j.jaci.2014.02.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sponzilli I, Notarangelo LD. Severe combined immunodeficiency (SCID): from molecular basis to clinical management. Acta Biomed (2011) 82(1):5–13. [PubMed] [Google Scholar]
  • 8.Gaspar HB, Qasim W, Davies EG, Rao K, Amrolia PJ, Veys P. How I treat severe combined immunodeficiency. Blood (2013) 122(23):3749–58. 10.1182/blood-2013-02-380105 [DOI] [PubMed] [Google Scholar]
  • 9.Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med (2014) 371(5):434–46. 10.1056/NEJMoa1401177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.McWilliams LM, Dell Railey M, Buckley RH. Positive family history, infection, low absolute lymphocyte count (ALC), and absent thymic shadow: diagnostic clues for all molecular forms of severe combined immunodeficiency (SCID). J Allergy Clin Immunol Pract (2015) 3(4):585–91. 10.1016/j.jaip.2015.01.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood (2011) 117(11):3243–6. 10.1182/blood-2010-08-300384 [DOI] [PubMed] [Google Scholar]
  • 12.Lee PP. Primary Immunodeficiency Disorders in Southeast Asia: Needs, Priorities and Opportunities [MD Thesis]. University of Hong Kong, Pokfulam, Hong Kong SAR: (2014). [Google Scholar]
  • 13.Lee PP, Chan KW, Chen TX, Jiang LP, Wang XC, Zeng HS, et al. Molecular diagnosis of severe combined immunodeficiency – identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children. J Clin Immunol (2011) 31(2):281–96. 10.1007/s10875-010-9489-z [DOI] [PubMed] [Google Scholar]
  • 14.Lee PP, Lau YL. Improving care, education, and research: the Asian primary immunodeficiency network. Ann N Y Acad Sci (2011) 1238:33–41. 10.1111/j.1749-6632.2011.06225.x [DOI] [PubMed] [Google Scholar]
  • 15.Krol DM, Keels MA. Oral conditions. Pediatr Rev (2007) 28(1):15–22. 10.1542/pir.28-1-15 [DOI] [PubMed] [Google Scholar]
  • 16.Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human gene mutation database (HGMD): 2003 update. Hum Mutat (2003) 21(6):577–81. 10.1002/humu.10212 [DOI] [PubMed] [Google Scholar]
  • 17.Piirilä H, Väliaho J, Vihinen M. Immunodeficiency mutation databases (IDbases). Hum Mutat (2006) 27(12):1200–8. 10.1002/humu.20405 [DOI] [PubMed] [Google Scholar]
  • 18.Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature (2016) 536(7616):285–91. 10.1038/nature19057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, et al. PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res (2017) 45(D1):D183–9. 10.1093/nar/gkw1138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics (2006) 22(22):2729–34. 10.1093/bioinformatics/btl423 [DOI] [PubMed] [Google Scholar]
  • 21.Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 4(7):1073–81. 10.1038/nprot.2009.86 [DOI] [PubMed] [Google Scholar]
  • 22.Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (2008) 24(24):2938–9. 10.1093/bioinformatics/btn564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Capriotti E, Altman RB, Bromberg Y. Collective judgment predicts disease-associated single nucleotide variants. BMC Genomics (2013) 14(Suppl 3):S2. 10.1186/1471-2164-14-S3-S2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods (2010) 7(4):248–9. 10.1038/nmeth0410-248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.NCBI Resource Coordinators. Database resources of the national center for biotechnology information. Nucleic Acids Res (2016) 44:D7–D19. 10.1093/nar/gkv1290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res (2015) 43(Database issue):D204–12. 10.1093/nar/gku989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kanai N, Yanai F, Hirose S, Nibu K, Izuhara K, Tani T, et al. A G to A transition at the last nucleotide of exon 6 of the gamma c gene (868G – >A) may result in either a splice or missense mutation in patients with X-linked severe combined immunodeficiency. Hum Genet (1999) 104(1):36–42. Erratum in: Hum Genet (1999) 104(2):196. 10.1007/s004390050907 [DOI] [PubMed] [Google Scholar]
  • 28.Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, De Saint-Basile G, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr (1993) 123(4):564–72. 10.1016/S0022-3476(05)80951-5 [DOI] [PubMed] [Google Scholar]
  • 29.Mazzucchelli JT, Bonfim C, Castro GG, Condino-Neto AA, Costa NM, Cunha L, et al. Severe combined immunodeficiency in Brazil: management, prognosis, and BCG-associated complications. J Investig Allergol Clin Immunol (2014) 24(3):184–91. [PubMed] [Google Scholar]
  • 30.Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N, Gharagozlou M, et al. Severe combined immunodeficiency: a cohort of 40 patients. Pediatr Allergy Immunol (2008) 19(4):303–6. 10.1111/j.1399-3038.2007.00647.x [DOI] [PubMed] [Google Scholar]
  • 31.Saleem AF, Ali Khawaja RD, Shaikh AS, Ali SA, Mehdi Zaidi AK. Severe combined immune deficiency syndrome. J Coll Physicians Surg Pak (2013) 23(8):570–3. [PubMed] [Google Scholar]
  • 32.Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol (2013) 33(7):1156–64. 10.1007/s10875-013-9917-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rozmus J, Junker A, Thibodeau ML, Grenier D, Turvey SE, Yacoub W, et al. Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study. J Clin Immunol (2013) 33(8):1310–6. 10.1007/s10875-013-9952-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med (2011) 8(3):e1001012. 10.1371/journal.pmed.1001012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.WHO. UNICEF: Immunization Summary, a Statistical Reference Containing Data through 2013. (2014). Available from: http://www.who.int/immunization/monitoring_surveillance/Immunization_Summary_2013.pdf
  • 36.Joung SM, Ryoo S. BCG vaccine in Korea. Clin Exp Vaccine Res (2013) 2(2):83–91. 10.7774/cevr.2013.2.2.83 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Wang JF, Dai FY, Gong XL, Bao L. Commonly administered bacilli Calmette–Guerin strains induce comparable immune response. Int J Clin Exp Med (2015) 8(9):15834–9. [PMC free article] [PubMed] [Google Scholar]
  • 38.Govindarajan KK, Chai FY. BCG adenitis-need for increased awareness. Malays J Med Sci (2011) 18(2):66–9. [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhang L, Ru HW, Chen FZ, Jin CY, Sun RF, Fan XY, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther (2016) 24(2):398–405. 10.1038/mt.2015.216 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet (2013) 381(9875):1405–16. 10.1016/S0140-6736(13)60222-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ (2008) 86(5):408–16. 10.2471/BLT.07.048769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gereige RS, Laufer PM. Pneumonia. Pediatr Rev (2013) 34(10):438–56; quiz 455–6. Erratum in: Pediatr Rev (2014) 35(1):29. 10.1542/pir.34-10-438 [DOI] [PubMed] [Google Scholar]
  • 43.Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. Pediatr Rev (2012) 33(4):156–63; quiz 163. 10.1542/pir.33-4-156 [DOI] [PubMed] [Google Scholar]
  • 44.Eguchi H, Horita N, Ushio R, Kato I, Nakajima Y, Ota E, et al. Diagnostic test accuracy of antigenemia assay for polymerase chain reaction proven cytomegalovirus infection: systematic review and meta-analysis. Clin Microbiol Infect (2017). 10.1016/j.cmi.2017.05.009 [DOI] [PubMed] [Google Scholar]
  • 45.Hamamy H. Consanguineous marriages: preconception consultation in primary health care settings. J Community Genet (2012) 3(3):185–92. 10.1007/s12687-011-0072-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Puck JM, Pepper AE, Henthorn PS, Candotti F, Isakov J, Whitwam T, et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood (1997) 89(6):1968–77. [PubMed] [Google Scholar]
  • 47.Walser JC, Furano AV. The mutational spectrum of non-CpG DNA varies with CpG content. Genome Res (2010) 20(7):875–82. 10.1101/gr.103283.109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang RY, Kuo KC, Gehrke CW, Huang LH, Ehrlich M. Heat- and alkali-induced deamination of 5-methylcytosine and cytosine residues in DNA. Biochim Biophys Acta (1982) 697(3):371–7. 10.1016/0167-4781(82)90101-4 [DOI] [PubMed] [Google Scholar]
  • 49.Ehrlich M, Zhang XY, Inamdar NM. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat Res (1990) 238(3):277–86. 10.1016/0165-1110(90)90019-8 [DOI] [PubMed] [Google Scholar]
  • 50.Ginn SL, Smyth C, Wong M, Bennetts B, Rowe PB, Alexander IE. A novel splice-site mutation in the common gamma chain (gammac) gene IL2RG results in X-linked severe combined immunodeficiency with an atypical NK+ phenotype. Hum Mutat (2004) 23(5):522–3. 10.1002/humu.9235 [DOI] [PubMed] [Google Scholar]
  • 51.Mou W, He J, Chen X, Zhang H, Ren X, Wu X, et al. A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype. Immunogenetics (2017) 69(1):29–38. 10.1007/s00251-016-0949-3 [DOI] [PubMed] [Google Scholar]
  • 52.Estévez OA, Ortega C, Fernández S, Aguado R, Rumbao J, Perez-Navero J, et al. A novel IL2RG mutation presenting with atypical T(−)B(+)NK+ phenotype: rapid elucidation of NK cell origin. Pediatr Blood Cancer (2014) 61(1):178–9. 10.1002/pbc.24717 [DOI] [PubMed] [Google Scholar]
  • 53.Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol (2014) 133(4):1099–108. 10.1016/j.jaci.2013.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Wu WC, Wang W, Song HM, Ma MS, Tang XY, Jian S, et al. [A major histocompatibility complex class II deficiency case report and literature review]. Zhonghua Er Ke Za Zhi (2016) 54(8):614–8. 10.3760/cma.j.issn.0578-1310.2016.08.013 [DOI] [PubMed] [Google Scholar]
  • 55.Shrestha D, Szöllosi J, Jenei A. Bare lymphocyte syndrome: an opportunity to discover our immune system. Immunol Lett (2012) 141(2):147–57. 10.1016/j.imlet.2011.10.007 [DOI] [PubMed] [Google Scholar]
  • 56.Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood (2011) 118(19):5108–18. 10.1182/blood-2011-05-352716 [DOI] [PubMed] [Google Scholar]
  • 57.Renella R, Picard C, Neven B, Ouachée-Chardin M, Casanova JL, Le Deist F, et al. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections. Br J Haematol (2006) 134(5):510–6. 10.1111/j.1365-2141.2006.06213.x [DOI] [PubMed] [Google Scholar]
  • 58.Mellouli F, Mustapha IB, Khaled MB, Besbes H, Ouederni M, Mekki N, et al. Report of the Tunisian registry of primary immunodeficiencies: 25-years of experience (1988–2012). J Clin Immunol (2015) 35(8):745–53. 10.1007/s10875-015-0206-9 [DOI] [PubMed] [Google Scholar]
  • 59.Bousfiha AA, Jeddane L, El Hafidi N, Benajiba N, Rada N, El Bakkouri J, et al. First report on the Moroccan registry of primary immunodeficiencies: 15 years of experience (1998–2012). J Clin Immunol (2014) 34(4):459–68. 10.1007/s10875-014-0005-8 [DOI] [PubMed] [Google Scholar]
  • 60.Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a single-center study. J Clin Immunol (2009) 29(3):343–51. 10.1007/s10875-008-9260-x [DOI] [PubMed] [Google Scholar]
  • 61.Kechout N, Attal N, Doudou F, Boukari R, Ardjoun M, Abbadi MC. Study of primary immunodeficiencies in Algeria. BMC Proc (2011) 5(Suppl 1):35. 10.1186/1753-6561-5-s1-p35 [DOI] [Google Scholar]
  • 62.Reda SM, El-Ghoneimy DH, Afifi HM. Clinical predictors of primary immunodeficiency diseases in children. Allergy Asthma Immunol Res (2013) 5(2):88–95. 10.4168/aair.2013.5.2.88 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Barbouche MR, Galal N, Ben-Mustapha I, Jeddane L, Mellouli F, Ailal F, et al. Primary immunodeficiencies in highly consanguineous North African populations. Ann N Y Acad Sci (2011) 1238:42–52. 10.1111/j.1749-6632.2011.06260.x [DOI] [PubMed] [Google Scholar]
  • 64.Naamane H, El Maataoui O, Ailal F, Barakat A, Bennani S, Najib J, et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr (2010) 169(9):1069–74. 10.1007/s00431-010-1179-6 [DOI] [PubMed] [Google Scholar]
  • 65.Elhasid R, Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev (1996) 10(4):242–8. 10.1016/S0268-960X(96)90008-9 [DOI] [PubMed] [Google Scholar]
  • 66.Kuo CY, Chase J, Garcia Lloret M, Stiehm ER, Moore T, Aguilera MJ, et al. Newborn screening for severe combined immunodeficiency does not identify bare lymphocyte syndrome. J Allergy Clin Immunol (2013) 131(6):1693–5. 10.1016/j.jaci.2013.01.019 [DOI] [PubMed] [Google Scholar]
  • 67.Hague RA, Rassam S, Morgan G, Cant AJ. Early diagnosis of severe combined immunodeficiency syndrome. Arch Dis Child (1994) 70(4):260–3. 10.1136/adc.70.4.260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Gennery AR, Cant AJ. Diagnosis of severe combined immunodeficiency. J Clin Pathol (2001) 54(3):191–5. 10.1136/jcp.54.3.191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol (2004) 22:625–55. 10.1146/annurev.immunol.22.012703.104614 [DOI] [PubMed] [Google Scholar]
  • 70.Rivers L, Gaspar HB. Severe combined immunodeficiency: recent developments and guidance on clinical management. Arch Dis Child (2015) 100(7):667–72. 10.1136/archdischild-2014-306425 [DOI] [PubMed] [Google Scholar]
  • 71.Kubiak C, Jyonouchi S, Kuo C, Garcia-Lloret M, Dorsey MJ, Sleasman J, et al. Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency. J Allergy Clin Immunol Pract (2014) 2(6):697–702. 10.1016/j.jaip.2014.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Distribution of age at diagnosis and time to diagnosis of patients with genetic diagnosis (n = 83). Distribution of age at diagnosis of patients with chronic diarrhea (A), severe infections (B), and lymphopenia (C) and distribution of time to diagnosis of patients with chronic diarrhea (D) and lymphopenia (E).


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES